Johnson Johnson AbbVie: Paths to Pharma Dominance
Johnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
This volatility comparison pits the dividend aristocrats ETF against the SP500 to help you evaluate relative risk and inform allocation decisions.
20,523 articlesJohnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Visa faces a mix of growth drivers and risks as digital payments expand globally. This piece outlines the visa stock ...
Occidental Petroleum leads the 2026 performance among three top U.S. energy explorers, with EOG Resources and ConocoP...
SpaceX gears up for the largest IPO in history on Nasdaq, while a 1:1 tokenized SpaceX equity trades on Solana. Backp...
Greg Abel, seen as Warren Buffett's successor, made a bold move by trimming UnitedHealth from Berkshire's portfolio. ...
Kick off your week with a focused investing routine. This article shares 10 Tuesday AM Reads you can digest in 15 min...
Apple’s measured AI approach contrasts with Microsoft’s aggressive spending, signaling a shift in investor bets as th...
Is Microsoft truly a value opportunity, or is the market pricing in all the worst fears? This deep-dive breaks down w...
A sharp 178% EPS rise is grabbing attention, paired with an insider stock sale at Rogers Corp. This article breaks do...
On a day of mixed signals, Bank of America and peers moved as tariffs and earnings chatter swirled. This article brea...
Radian Group's Q1 2026 earnings narrative reveals how the mortgage insurance business is performing, how risk is mana...
The latest trustees report signals coming pressures on Social Security. This guide breaks down what that means for ev...